COSTAR: A Multicentre Randomised Study of Cochlear Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy in Patients with Parotid Tumours.
Disease site: Head and neck
Treatment modality: Radiotherapy
Status: In active follow-up
COSTAR is a phase III multi-centre randomised controlled trial designed to demonstrate a difference in the proportion of patients suffering sensori-neural hearing loss of at least 10dB in bone conduction at 4000 Hz, as assessed by an audiogram done 12 months post radiotherapy, in patients treated with cochlea-sparing IMRT and conventional radiotherapy.
The work is supported by the NCRI CTrad Group and the NCRI Head and Neck Cancer Studies Group.
Chief Investigator: Dr Chris Nutting, The Royal Marsden NHS Foundation Trust
ICR-CTSU Scientific Lead: Dr Emma Hall
Trial management contact: Mark Sydenham - Trial Manager, [email protected]
Sponsor: The Royal Marsden NHS Foundation Trust
Funding: Cancer Research UK (CRUK/08/004)
Further information on the COSTAR trial may be found on the following sites:
Accrual figures are available from the UK Clinical Trials Gateway
Patient friendly information on the COSTAR trial at CancerHelp UK